MX9303958A - Derivados de tiazolilvinilfenilo, procedimiento para su preparacion y medicamento que los contiene. - Google Patents

Derivados de tiazolilvinilfenilo, procedimiento para su preparacion y medicamento que los contiene.

Info

Publication number
MX9303958A
MX9303958A MX9303958A MX9303958A MX9303958A MX 9303958 A MX9303958 A MX 9303958A MX 9303958 A MX9303958 A MX 9303958A MX 9303958 A MX9303958 A MX 9303958A MX 9303958 A MX9303958 A MX 9303958A
Authority
MX
Mexico
Prior art keywords
thiazolylvinylphenyl
derivatives
procedure
preparation
medication containing
Prior art date
Application number
MX9303958A
Other languages
English (en)
Inventor
George William Holland
John Raymond Vermeulen
William Joseph Zally
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX9303958A publication Critical patent/MX9303958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos de la fórmula I: y sus enantiómeros, diastereómeros, racematos y sales con bases farmacéuticamente aceptables, antagonizan la acción de LTD4 y son útiles, por tanto, en el tratamiento de asma bronquial, anafilaxis pulmonar, fibrosis cística, bronquitis crónica, bronquiectasis, síndrome de disnea y edema pulmonar.
MX9303958A 1992-07-02 1993-06-30 Derivados de tiazolilvinilfenilo, procedimiento para su preparacion y medicamento que los contiene. MX9303958A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/907,987 US5273986A (en) 1992-07-02 1992-07-02 Cycloalkylthiazoles

Publications (1)

Publication Number Publication Date
MX9303958A true MX9303958A (es) 1994-04-29

Family

ID=25424972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303958A MX9303958A (es) 1992-07-02 1993-06-30 Derivados de tiazolilvinilfenilo, procedimiento para su preparacion y medicamento que los contiene.

Country Status (18)

Country Link
US (2) US5273986A (es)
EP (1) EP0577003A1 (es)
JP (1) JPH0680654A (es)
KR (1) KR940005602A (es)
CN (1) CN1087086A (es)
AU (1) AU667107B2 (es)
BR (1) BR9302737A (es)
CA (1) CA2099295A1 (es)
CZ (1) CZ133493A3 (es)
FI (1) FI933037A (es)
HU (1) HUT72747A (es)
IL (1) IL106141A0 (es)
MX (1) MX9303958A (es)
NO (1) NO932399L (es)
NZ (1) NZ247988A (es)
PL (1) PL299544A1 (es)
UY (1) UY23609A1 (es)
ZA (1) ZA934603B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
AU3522895A (en) * 1994-09-13 1996-03-29 F. Hoffmann-La Roche Ag A process of making (e)-4-{3-{2-(4-cycloalkyl-2-thiazolyl) ethenyl}phenyl}amino-2 ,2-alkyldiyl-4-oxobutanoic acid anoic acid
RU2161612C2 (ru) * 1994-10-14 2001-01-10 Яманоути Фармасьютикал Ко., Лтд. Производные азола, фармацевтическая композиция на их основе, промежуточные соединения
AU5347496A (en) * 1995-04-21 1996-11-07 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
SE9804212D0 (sv) * 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
US7056917B2 (en) * 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2002087589A1 (fr) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Medicament permettant d'inhiber une pompe d'elimination de medicament
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP2048137A1 (en) * 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
BRPI0507734A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2005293343B2 (en) 2004-10-16 2009-03-19 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1902052B1 (en) * 2005-07-09 2012-11-28 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2007007040A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
BRPI0721143A2 (pt) * 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
AU2009278929B2 (en) 2008-08-04 2012-07-05 Astrazeneca Ab Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116176A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN102647984B (zh) 2009-10-02 2015-03-25 埃维克辛公司 抗炎症的2-羰基噻唑和2-羰基恶唑
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20220324835A1 (en) * 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
CN114364667A (zh) 2019-04-09 2022-04-15 紐力克斯治疗公司 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途
JP2022532247A (ja) 2019-05-17 2022-07-13 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
DE3723913A1 (de) * 1987-07-18 1989-02-23 Shell Agrar Gmbh & Co Kg Neue phosphoniumsalze, ihre herstellung und verwendung
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
ES2052825T3 (es) * 1988-07-15 1994-07-16 Hoffmann La Roche Derivados de cicloalquiltiazol.
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH02169583A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
AU654140B2 (en) * 1990-07-31 1994-10-27 Lilly Industries Limited N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HUT72747A (en) 1996-05-28
EP0577003A1 (en) 1994-01-05
UY23609A1 (es) 1993-12-21
CN1087086A (zh) 1994-05-25
HU9301881D0 (en) 1993-09-28
NO932399L (no) 1994-01-03
US5399702A (en) 1995-03-21
JPH0680654A (ja) 1994-03-22
US5273986A (en) 1993-12-28
KR940005602A (ko) 1994-03-21
AU4156293A (en) 1994-01-06
BR9302737A (pt) 1994-02-08
IL106141A0 (en) 1993-10-20
ZA934603B (en) 1994-01-05
AU667107B2 (en) 1996-03-07
CA2099295A1 (en) 1994-01-03
CZ133493A3 (en) 1994-01-19
PL299544A1 (en) 1994-02-21
NZ247988A (en) 1995-11-27
NO932399D0 (no) 1993-07-01
FI933037A0 (fi) 1993-07-01
FI933037A (fi) 1994-01-03

Similar Documents

Publication Publication Date Title
MX9303958A (es) Derivados de tiazolilvinilfenilo, procedimiento para su preparacion y medicamento que los contiene.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
NO996068D0 (no) Piperazinderivater og deres anvendelse som anti- inflammatoriske midler
MX9304359A (es) Derivados de rapamicina.
ES2116131T3 (es) Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2115985T3 (es) Dihidropirazolopirroles.
EA200100202A1 (ru) 4-карбоксиамино-2-замещенные-1,2,3,4-тетрагидрохинолины в качестве сетр-ингибиторов
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
FI946083A (fi) Antianginaaliset purinonit
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
MX9404885A (es) Derivados de ariliden y heteroariliden oxindoles, proceso para supreparacion y composiciones farmaceuticas que los contienen.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
PT99597B (pt) Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase
NO954878L (no) Pyrrolderivater
ES2179091T3 (es) Barniz de proteccion para madera.
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
ES2126674T3 (es) Empleo de o-esteres de l-carnitina con acidos aromaticos para el tratamiento de dermatosis.
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
FI932654A (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
FI965097A0 (fi) Substituoidut alkyylidiamiinijohdannaiset ja niiden käyttö takykiniini antagonisteina